NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

GSK PLC GSK shares advanced 2.13% to £14.84 Tuesday, on what proved to be an all-around positive trading session for the ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

GSK PLC closed 20.35% short of its 52-week high of £18.24, which the company achieved on May 16th.

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a ...

The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

London, UK Tuesday, February 25, 2025, 15:00 Hrs [IST] GSK plc (GSK) announces the commencement of its share buyback programme (the “Progr ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...